Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Improved formulation of Testoderm available in U.S.

Oct. 11, 1996

Muse approvable for treatment of impotence

Oct. 11, 1996

Aldose reductase inhibitor in phase III at Fujisawa

Oct. 11, 1996

Antidiabetic agents from Yamanouchi's clinical pipeline

Oct. 11, 1996

New approval for Lilly's Humalog

Oct. 11, 1996

UCSF scientists discover protein involved in insulin resistance

Oct. 11, 1996

Novel, highly potent antihyperglycemic agents from SmithKline Beecham

Oct. 11, 1996

Nissan Chem. claims hypoglycemic agents for diabetes

Oct. 11, 1996

Progress in development of NPS's R-568

Oct. 11, 1996

Future metabolic agents in the Yamanouchi pipeline

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...